{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T21:12:38Z","timestamp":1776978758407,"version":"3.51.4"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s12185-022-03511-9","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T20:04:45Z","timestamp":1670529885000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic myeloid leukemia: the cutting-edge evidence and things we should know"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-1988","authenticated-orcid":false,"given":"Noriyoshi","family":"Iriyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"3511_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03446-1","author":"Z Narl\u0131 \u00d6zdemir","year":"2022","unstructured":"Narl\u0131 \u00d6zdemir Z, K\u0131l\u0131\u00e7aslan NA, Y\u0131lmaz M, E\u015fkazan AE. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol. 2022. https:\/\/doi.org\/10.1007\/s12185-022-03446-1.","journal-title":"Int J Hematol"},{"key":"3511_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03432-7","author":"A Lagan\u00e0","year":"2022","unstructured":"Lagan\u00e0 A, Scalzulli E, Carmosino I, Martelli M, Breccia M. Asciminib as a third line option in chronic myeloid leukemia. Int J Hematol. 2022. https:\/\/doi.org\/10.1007\/s12185-022-03432-7.","journal-title":"Int J Hematol"},{"key":"3511_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03431-8","author":"Y Umezawa","year":"2022","unstructured":"Umezawa Y, Sasaki K. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Int J Hematol. 2022. https:\/\/doi.org\/10.1007\/s12185-022-03431-8.","journal-title":"Int J Hematol"},{"key":"3511_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03510-w","author":"Y Ochi","year":"2022","unstructured":"Ochi Y. Genetic landscape of chronic myeloid leukemia. Int J Hematol. 2022. https:\/\/doi.org\/10.1007\/s12185-022-03510-w.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03511-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03511-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03511-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:11:45Z","timestamp":1672841505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03511-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3511"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03511-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N. Iriyama received honoraria and speaker fees from Bristol-Myers Squibb and Novartis Pharma K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}